ARS Pharmaceuticals, Inc.

For the period ended Jun 30, 2025. Filed Aug 13, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 13, 2025

SPRY$3.57+13.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share data)

	Three Months Ended June 30,		Six Months Ended June 30,
	2025	2024	2025	2024
Revenue:
Product revenue, net	$12,800	$—	$20,563	$—
Revenue under collaboration agreements	2,594	500	2,804	500
Revenue under supply agreements	323	—	323	—
Total revenue	15,717	500	23,690	500
Operating expenses:
Cost of goods sold (including related party amounts of $866, $0, $1,354, and $0, respectively)	4,984	—	6,078	—
Research and development (including related party amounts of $582, $518, $1,245, and $1,245, respectively)	4,035	6,896	6,987	12,130
Selling, general and administrative (including related party amounts of $107, $114, $231, and $208, respectively)	54,312	8,944	95,416	16,902
Total operating expenses	63,331	15,840	108,481	29,032
Loss from operations	(47,614)	(15,340)	(84,791)	(28,532)
Other income, net	2,731	2,824	5,968	5,724
Net loss	$(44,883)	$(12,516)	$(78,823)	$(22,808)
Change in unrealized gains and losses on available-for-sale securities	(118)	(21)	(266)	(194)
Comprehensive loss	$(45,001)	$(12,537)	$(79,089)	$(23,002)
Net loss per share, basic and diluted	$(0.46)	$(0.13)	$(0.80)	$(0.24)
Weighted-average shares outstanding used in computing net loss per share, basic and diluted	98,361,771	96,827,687	98,212,035	96,656,690

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.